Screener
BioMarin Pharmaceuticals BMRN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's total equity?
- BioMarin Pharmaceuticals (BMRN) reported total equity of $6.32B in Q2 2026.
- How has BioMarin Pharmaceuticals's total equity changed year-over-year?
- BioMarin Pharmaceuticals's total equity increased by 4.9% year-over-year, from $6.03B to $6.32B.
- What is the long-term trend for BioMarin Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total equity has grown at a 8.2% compound annual growth rate (CAGR), from $4.1B to $6.09B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about BioMarin Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude